Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma

Baykara M., Akkus M., YILDIZ R., IŞIK GÖNÜL İ. , DURSUN A. , Coskun U., ...More

INTERNATIONAL IMMUNOPHARMACOLOGY, vol.11, no.12, pp.2227-2231, 2011 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 12
  • Publication Date: 2011
  • Doi Number: 10.1016/j.intimp.2011.10.005
  • Page Numbers: pp.2227-2231


This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in gastrointestinal stromal sarcoma (GIST). Twenty patients (12 males and 8 females) ranging in age from 25 to 72, with a median age of 53 were evaluated. Failure of TKI treatment was higher in the survivin-positive group (p= 0.06). The rate of metastasis was significantly higher in the survivin positive group vs. the negative group (80% vs. 30%, p =0.18). The median overall survival (OS) time was 114 (range 29-199) months, and the median disease-free survival (DFS) time was 88 (range 40-135) months. The median progression-free survival (PFS) time was 40 (range 24-55) months. Further, a comparison of patients with survivin positive versus negative tumors, revealed no significant difference for OS, DFS, and PFS (p = 0.45, p = 0.19, p= 0.55, respectively), number of mitoses in 50 HPF (p =0.14), and tumor size (p = 0.94).